相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD
Na Jiao et al.
GUT (2018)
FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity
Xiaoxin X. Wang et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Identification of an Oleanane-Type Triterpene Hedragonic Acid as a Novel Farnesoid X Receptor Ligand with Liver Protective Effects and Anti-inflammatory Activity
Yi Lu et al.
MOLECULAR PHARMACOLOGY (2018)
Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression
O. Erice et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2018)
Farnesoid X receptor: A homeostat for hepatic nutrient metabolism
Vittoria Massafra et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2018)
Curcumin regulates endogenous and exogenous metabolism via Nrf2-FXR-LXR pathway in NAFLD mice
Caixia Yan et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Adiponectin determines farnesoid X receptor agonism-mediated cardioprotection against post-infarction remodelling and dysfunction
Yunlong Xia et al.
CARDIOVASCULAR RESEARCH (2018)
Farnesoid X receptor modulators 2014-present: a patent review
Valentina Sepe et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2018)
-Catenin regulation of farnesoid X receptor signaling and bile acid metabolism during murine cholestasis
Michael D. Thompson et al.
HEPATOLOGY (2018)
Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism
Preeti Pathak et al.
HEPATOLOGY (2018)
Farnesoid X receptor signaling activates the hepatic X-box binding protein 1 pathway in vitro and in mice
Xiaoying Liu et al.
HEPATOLOGY (2018)
Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice
Phillipp Hartmann et al.
HEPATOLOGY (2018)
INT-767 prevents NASH and promotes visceral fat brown adipogenesis and mitochondrial function
Paolo Comeglio et al.
JOURNAL OF ENDOCRINOLOGY (2018)
HS218 as an FXR antagonist suppresses gluconeogenesis by inhibiting FXR binding to PGC-1α promoter
Xin Xu et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2018)
Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-κB Signaling, and Hepatic Inflammation
Zhibo Gai et al.
MOLECULAR PHARMACOLOGY (2018)
Farnesoid X receptor antagonist exacerbates dyslipidemia in mice
Yuichiro Amano et al.
PHARMACOLOGICAL REPORTS (2018)
Disruption of TFGβ-SIVIAD3 pathway by the nuclear receptor SHP mediates the antifibrotic activities of BAR704, a novel highly selective FXR ligand
Adriana Carino et al.
PHARMACOLOGICAL RESEARCH (2018)
Farnesoid X receptor is essential for the survival of renal medullary collecting duct cells under hypertonic stress
Sujuan Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed nonalcoholic steatohepatitis
Jonathan D. Roth et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR
Kavita Jadhav et al.
MOLECULAR METABOLISM (2018)
Xenobiotic Nuclear Receptor Signaling Determines Molecular Pathogenesis of Progressive Familial Intrahepatic Cholestasis
Kang Ho Kim et al.
ENDOCRINOLOGY (2018)
AMPK activation by liquiritigenin inhibited oxidative hepatic injury and mitochondrial dysfunction induced by nutrition deprivation as mediated with induction of farnesoid X receptor
Eun Hye Jung et al.
EUROPEAN JOURNAL OF NUTRITION (2017)
Alisol B 23-acetate protects against non-alcoholic steatohepatitis in mice via farnesoid X receptor activation
Qiang Meng et al.
ACTA PHARMACOLOGICA SINICA (2017)
An Intestinal Farnesoid X Receptor-Ceramide Signaling Axis Modulates Hepatic Gluconeogenesis in Mice
Cen Xie et al.
DIABETES (2017)
Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor-dependent inhibition of hepatic stellate cell contraction
Wenxuan Xu et al.
FEBS JOURNAL (2017)
Microbiota-induced obesity requires farnesoid X receptor
Ava Parseus et al.
GUT (2017)
A rapid administration of GW4064 inhibits the NLRP3 inflammasome activation independent of farnesoid X receptor agonism
Shujun Xie et al.
FEBS LETTERS (2017)
Intestinal Farnesoid X Receptor Controls Transintestinal Cholesterol Excretion in Mice
Jan Freark de Boer et al.
GASTROENTEROLOGY (2017)
Farnesoid X Receptor Activation Promotes Hepatic Amino Acid Catabolism and Ammonium Clearance in Mice
Vittoria Massafra et al.
GASTROENTEROLOGY (2017)
Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease
Oscar Chavez-Talavera et al.
GASTROENTEROLOGY (2017)
Defining the Relationship Between Farsenoid X Receptor, Hepatitis B Virus X Protein and Hepatocellular Carcinoma: It's Complicated
Lindsey Kennedy et al.
HEPATOLOGY (2017)
Farnesoid X Receptor Ablation Sensitizes Mice to Hepatitis B Virus X Protein-Induced Hepatocarcinogenesis
Yongdong Niu et al.
HEPATOLOGY (2017)
Hepatic FXR/SHP Axis Modulates Systemic Glucose and Fatty Acid Homeostasis in Aged Mice
Kang Ho Kim et al.
HEPATOLOGY (2017)
Small Heterodimer Partner Deletion Prevents Hepatic Steatosis and When Combined With Farnesoid X Receptor Loss Protects Against Type 2 Diabetes in Mice
Oludemilade Akinrotimi et al.
HEPATOLOGY (2017)
A dual agonist of farnesoid X receptor (FXR) and the G protein-coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice
Xiaoxin X. Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism
Preeti Pathak et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15
Mei Zhou et al.
JOURNAL OF HEPATOLOGY (2017)
Steroidal or non-steroidal FXR agonists - Is that the question?
Len Verbeke et al.
JOURNAL OF HEPATOLOGY (2017)
The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction
Philipp Schwabl et al.
JOURNAL OF HEPATOLOGY (2017)
Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
David C. Tully et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Activation of FXR pathway does not alter glial cell function
Stefanie Albrecht et al.
JOURNAL OF NEUROINFLAMMATION (2017)
Farnesoid X Receptor Agonism Protects against Diabetic Tubulopathy: Potential Add-On Therapy for Diabetic Nephropathy
Andi Marquardt et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Hepatocyte Nuclear Factor-1β Regulates Urinary Concentration and Response to Hypertonicity
Karam Aboudehen et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Altenusin, a Nonsteroidal Microbial Metabolite, Attenuates Nonalcoholic Fatty Liver Disease by Activating the Farnesoid X Receptor
Zhihui Zheng et al.
MOLECULAR PHARMACOLOGY (2017)
Mechanisms of hepatic stellate cell activation
Takuma Tsuchida et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
Alisol B 23-acetate from the rhizomes of Alisma orientale is a natural agonist of the human pregnane X receptor
Yuichiro Kanno et al.
PHYTOMEDICINE (2017)
Farnesoid X Receptor Protects Against Low-Dose Carbon Tetrachloride-Induced Liver Injury Through the Taurocholate-JNK Pathway
Shogo Takahashi et al.
TOXICOLOGICAL SCIENCES (2017)
Protective effects of dioscin against doxorubicin-induced nephrotoxicity via adjusting FXR-mediated oxidative stress and inflammation
Yimeng Zhang et al.
TOXICOLOGY (2017)
Dihydroartemisinin protects against alcoholic liver injury through alleviating hepatocyte steatosis in a farnesoid X receptor-dependent manner
Wenxuan Xu et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2017)
miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice
Pedro M. Rodrigues et al.
CELL DEATH & DISEASE (2017)
Activation of Sirt1/FXR Signaling Pathway Attenuates Triptolide-Induced Hepatotoxicity in Rats
Jing Yang et al.
FRONTIERS IN PHARMACOLOGY (2017)
BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis
Adriana Carino et al.
SCIENTIFIC REPORTS (2017)
Farnesoid X receptor, a novel protooncogene in non-small cell lung cancer, promotes tumor growth via directly transactivating CCND1
Wenjie You et al.
SCIENTIFIC REPORTS (2017)
Gender Differences in Bile Acids and Microbiota in Relationship with Gender Dissimilarity in Steatosis Induced by Diet and FXR Inactivation
Lili Sheng et al.
SCIENTIFIC REPORTS (2017)
Farnesoid X receptor activation protects the kidney from ischemia-reperfusion damage
Zhibo Gai et al.
SCIENTIFIC REPORTS (2017)
Farnesoid-X Receptor (FXR) as a Promising Pharmaceutical Target in Atherosclerosis
Demetrios Moris et al.
CURRENT MEDICINAL CHEMISTRY (2017)
MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR
Hezhongrong Nie et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2017)
High Farnesoid X Receptor (FXR) expression is a strong and independent prognosticator in invasive breast carcinoma
C. Giaginis et al.
NEOPLASMA (2017)
Farnesoid X Receptor and Liver X Receptor Ligands Initiate Formation of Coated Platelets
Amanda J. Unsworth et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2017)
FXR-Gankyrin axis is involved in development of pediatric liver cancer
Leila Valanejad et al.
CARCINOGENESIS (2017)
Farnesoid X Receptor Regulation of the NLRP3 Inflammasome Underlies Cholestasis-Associated Sepsis
Haiping Hao et al.
CELL METABOLISM (2017)
Targeting the Gut Microbiota-FXR Signaling Axis for Glycemic Control: Does a Dietary Supplement Work Magic?
Show-Ling Shyng
DIABETES (2017)
Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice
Zhibo Gai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Obeticholic acid for the treatment of primary biliary cirrhosis
Palak J. Trivedi et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2016)
Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
Timothy Hardy et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 11 (2016)
Farnesoid X Receptor and Its Ligands Inhibit the Function of Platelets
Leonardo A. Moraes et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)
Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis
Nicole M. Kettner et al.
CANCER CELL (2016)
FXR Agonists: From Bench to Bedside, a Guide for Clinicians
Ahmad Samer Alawad et al.
DIGESTIVE DISEASES AND SCIENCES (2016)
Identification of functional farnesoid X receptors in brain neurons
Chao Huang et al.
FEBS LETTERS (2016)
Sirtuin 1 Activation Alleviates Cholestatic Liver Injury in a Cholic Acid-Fed Mouse Model of Cholestasis
Supriya R. Kulkarni et al.
HEPATOLOGY (2016)
Dihydroartemisinin Restricts Hepatic Stellate Cell Contraction via an FXR-S1PR2-dependent Mechanism
Wenxuan Xu et al.
IUBMB LIFE (2016)
Silymarin Ameliorates Metabolic Dysfunction Associated with Diet-Induced Obesity via Activation of Farnesyl X Receptor
Ming Gu et al.
FRONTIERS IN PHARMACOLOGY (2016)
Farnesoid X receptor activation promotes cell proliferation via PDK4-controlled metabolic reprogramming
Yang Xie et al.
SCIENTIFIC REPORTS (2016)
Curcumin protects ANIT-induced cholestasis through signaling pathway of FXR-regulated bile acid and inflammation
Fan Yang et al.
SCIENTIFIC REPORTS (2016)
Activation of FXR protects against renal fibrosis via suppressing Smad3 expression
Kai Zhao et al.
SCIENTIFIC REPORTS (2016)
Tissue-specific actions of FXR in metabolism and cancer
Raffaella Maria Gadaleta et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2015)
Excessive bile acid activated NF-kappa B and promoted the development of alcoholic steatohepatitis in farnesoid X receptor deficient mice
Wei-Bin Wu et al.
BIOCHIMIE (2015)
Role of FXR in β-Cells of Lean and Obese Mice
Bjoern Schittenhelm et al.
ENDOCRINOLOGY (2015)
Curcumin attenuates ethanol-induced hepatic steatosis through modulating Nrf2/FXR signaling in hepatocytes
Chunfeng Lu et al.
IUBMB LIFE (2015)
Implications of microbiota and bile acid in liver injury and regeneration
Hui-Xin Liu et al.
JOURNAL OF HEPATOLOGY (2015)
Chenodeoxycholic acid, an endogenous FXR ligand alters adipokines and reverses insulin resistance
Mohamed Sham Shihabudeen et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2015)
Activated farnesoid X receptor attenuates apoptosis and liver injury in autoimmune hepatitis
Fan Lian et al.
MOLECULAR MEDICINE REPORTS (2015)
Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
Sungsoon Fang et al.
NATURE MEDICINE (2015)
Protective Effects of Alisol B 23-Acetate Via Farnesoid X Receptor-Mediated Regulation of Transporters and Enzymes in Estrogen-Induced Cholestatic Liver Injury in Mice
Qiang Meng et al.
PHARMACEUTICAL RESEARCH (2015)
Alisol B 23-acetate protects against ANIT-induced hepatotoxity and cholestasis, due to FXR-mediated regulation of transporters and enzymes involved in bile acid homeostasis
Qiang Meng et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2015)
Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells
Mohamed-Sami Trabelsi et al.
NATURE COMMUNICATIONS (2015)
Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
Changtao Jiang et al.
NATURE COMMUNICATIONS (2015)
Protective effects of alisol B 23-acetate from edible botanical Rhizoma alismatis against carbon tetrachloride-induced hepatotoxicity in mice
Qiang Meng et al.
FOOD & FUNCTION (2015)
FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach
Weiqiang Lu et al.
SCIENTIFIC REPORTS (2015)
Farnesoid X receptor, the bile acid sensing nuclear receptor, in liver regeneration
Guodong Li et al.
ACTA PHARMACEUTICA SINICA B (2015)
FXR and liver carcinogenesis
Xiong-fei Huang et al.
ACTA PHARMACOLOGICA SINICA (2015)
Prevention of Spontaneous Hepatocarcinogenesis in Farnesoid X Receptor-Null Mice by Intestinal-Specific Farnesoid X Receptor Reactivation
Chiara Degirolamo et al.
HEPATOLOGY (2015)
Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
Changtao Jiang et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Activation of farnesoid X receptor (FXR) protects against fructose-induced liver steatosis via inflammatory inhibition and ADRP reduction
Xijun Liu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease
Weibin Wu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
Alisol B 23-acetate promotes liver regeneration in mice after partial hepatectomy via activating farnesoid X receptor
Qiang Meng et al.
BIOCHEMICAL PHARMACOLOGY (2014)
SIRT1 Controls Liver Regeneration by Regulating Bile Acid Metabolism Through Farnesoid X Receptor and Mammalian Target of Rapamycin Signaling
Juan L. Garcia-Rodriguez et al.
HEPATOLOGY (2014)
Farnesoid X Receptor Ligand Prevents Cisplatin-Induced Kidney Injury by Enhancing Small Heterodimer Partner
Eun Hui Bae et al.
PLOS ONE (2014)
Impact of Global Fxr Deficiency on Experimental Acute Pancreatitis and Genetic Variation in the FXR Locus in Human Acute Pancreatitis
Rian M. Nijmeijer et al.
PLOS ONE (2014)
Farnesoid X receptor regulates forkhead Box O3a activation in ethanol-induced autophagy and hepatotoxicity
Sharon Manley et al.
REDOX BIOLOGY (2014)
The Role of Bile Salt Export Pump Gene Repression in Drug-Induced Cholestatic Liver Toxicity
Brandy Garzel et al.
DRUG METABOLISM AND DISPOSITION (2014)
Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis
Lars P. Bechmann et al.
HEPATOLOGY (2013)
Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice
Guodong Li et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2013)
FXR ligands protect against hepatocellular inflammation via SOCS3 induction
Zhizhen Xu et al.
CELLULAR SIGNALLING (2012)
Farnesoid X Receptor Protects Hepatocytes From Injury by Repressing miR-199a-3p, Which Increases Levels of LKB1
Chan Gyu Lee et al.
GASTROENTEROLOGY (2012)
Selective Activation of Nuclear Bile Acid Receptor FXR in the Intestine Protects Mice Against Cholestasis
Salvatore Modica et al.
GASTROENTEROLOGY (2012)
Promotion of Liver Regeneration/Repair by Farnesoid X Receptor in Both Liver and Intestine in Mice
Lisheng Zhang et al.
HEPATOLOGY (2012)
Deletion of IFNγ enhances hepatocarcinogenesis in FXR knockout mice
Zhipeng Meng et al.
JOURNAL OF HEPATOLOGY (2012)
Discovery That Theonellasterol a Marine Sponge Sterol Is a Highly Selective FXR Antagonist That Protects against Liver Injury in Cholestasis
Barbara Renga et al.
PLOS ONE (2012)
The significance of the nuclear farnesoid X receptor (FXR) in β cell function
Martina Düfer et al.
Islets (2012)
Synthetic Farnesoid X Receptor Agonists Induce High-Density Lipoprotein-Mediated Transhepatic Cholesterol Efflux in Mice and Monkeys and Prevent Atherosclerosis in Cholesteryl Ester Transfer Protein Transgenic Low-Density Lipoprotein Receptor (-/-) Mice
Eva Hambruch et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter
Barbara Renga et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2011)
Nuclear receptors in renal disease
Moshe Levi
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2011)
Nuclear bile acid receptor FXR in the hepatic regeneration
Wei-Dong Chen et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2011)
Farnesoid X receptor agonists for primary biliary cirrhosis
Keith D. Lindor
CURRENT OPINION IN GASTROENTEROLOGY (2011)
Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease
Raffaella M. Gadaleta et al.
GUT (2011)
Dual Farnesoid X Receptor/TGR5 Agonist INT-767 Reduces Liver Injury in the Mdr2-/- (Abcb4-/-) Mouse Cholangiopathy Model by Promoting Biliary HCO3- Output
Anna Baghdasaryan et al.
HEPATOLOGY (2011)
SHP-dependent and -independent induction of peroxisome proliferator-activated receptor-γ by the bile acid sensor farnesoid X receptor counter-regulates the pro-inflammatory phenotype of liver myofibroblasts
Barbara Renga et al.
INFLAMMATION RESEARCH (2011)
Combined deletion of Fxr and Shp in mice induces Cyp17a1 and results in juvenile onset cholestasis
Sayeepriyadarshini Anakk et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Roles of microRNA-29a in the Antifibrotic Effect of Farnesoid X Receptor in Hepatic Stellate Cells
Jiang Li et al.
MOLECULAR PHARMACOLOGY (2011)
Hepatic FXR: key regulator of whole-body energy metabolism
Joao Soeiro Teodoro et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2011)
The bile acid sensor FXR regulates insulin transcription and secretion
Barbara Renga et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2010)
The nuclear receptor FXR is expressed in pancreatic β-cells and protects human islets from lipotoxicity
Iuliana Ristea Popescu et al.
FEBS LETTERS (2010)
Liver X Receptor α and Farnesoid X Receptor Are Major Transcriptional Regulators of OATP1B1
Henriette E. Meyer Zu Schwabedissen et al.
HEPATOLOGY (2010)
Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease
Zhao-Xia Yang et al.
HEPATOLOGY INTERNATIONAL (2010)
FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats
Sabrina Cipriani et al.
JOURNAL OF LIPID RESEARCH (2010)
FXR Regulates Liver Repair after CCl4-Induced Toxic Injury
Zhipeng Meng et al.
MOLECULAR ENDOCRINOLOGY (2010)
Functional Characterization of the Semisynthetic Bile Acid Derivative INT-767, a Dual Farnesoid X Receptor and TGR5 Agonist
Giovanni Rizzo et al.
MOLECULAR PHARMACOLOGY (2010)
Inhibition of Endothelin-1-Mediated Contraction of Hepatic Stellate Cells by FXR Ligand
Jiang Li et al.
PLOS ONE (2010)
Farnesoid X Receptor Critically Determines the Fibrotic Response in Mice but Is Expressed to a Low Extent in Human Hepatic Stellate Cells and Periductal Myofibroblasts
Peter Fickert et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
FXR Acetylation Is Normally Dynamically Regulated by p300 and SIRT1 but Constitutively Elevated in Metabolic Disease States
Jongsook Kim Kemper et al.
CELL METABOLISM (2009)
Farnesoid X receptor agonists in biliary tract disease
Stefano Fiorucci et al.
CURRENT OPINION IN GASTROENTEROLOGY (2009)
Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis
Songwen Zhang et al.
JOURNAL OF HEPATOLOGY (2009)
Nuclear Bile Acid Receptor FXR Protects against Intestinal Tumorigenesis
Salvatore Modica et al.
CANCER RESEARCH (2008)
FXR: a metabolic regulator and cell protector
Yan-Dong Wang et al.
CELL RESEARCH (2008)
Loss of orphan receptor small heterodimer partner sensitizes mice to liver injury from obstructive cholestasis
Young Joo Park et al.
HEPATOLOGY (2008)
Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy
Tao Jiang et al.
DIABETES (2007)
Targeting farnesoid X receptor for liver and metabolic disorders
Stefano Fiorucci et al.
TRENDS IN MOLECULAR MEDICINE (2007)
Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor
Fan Yang et al.
CANCER RESEARCH (2007)
The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo
Giovanni Rizzo et al.
MOLECULAR PHARMACOLOGY (2006)
FXR, a multipurpose nuclear receptor
Florence Y. Lee et al.
TRENDS IN BIOCHEMICAL SCIENCES (2006)
Benefit of farnesoid X receptor inhibition in obstructive cholestasis
Catherine Stedman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Coordinated induction of bile acid detoxification and alternative elimination in mice:: role of FXR-regulated organic solute transporter-α/β in the adaptive response to bile acids
G Zollner et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2006)
Role of nuclear receptors in the adaptive response to bile acids and cholestasis: Pathogenetic and therapeutic considerations
Gernot Zollner et al.
MOLECULAR PHARMACEUTICS (2006)
The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice
B Cariou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration
WD Huang et al.
SCIENCE (2006)
Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor
T Inagaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Upregulation of a basolateral FXR-dependent bile acid efflux transporter OST alpha-OST beta in cholestasis in humans and rodents
James L. Boyer et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2006)
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
T Inagaki et al.
CELL METABOLISM (2005)
Cross-talk between farnesoid-X-receptor (FXR)and peroxisome proliferator-activated receptor γ contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis
S Fiorucci et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
A farnesoid X receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis
S Fiorucci et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis
S Fiorucci et al.
GASTROENTEROLOGY (2004)
Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine
G Zollner et al.
JOURNAL OF HEPATOLOGY (2003)
Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice
M Wagner et al.
GASTROENTEROLOGY (2003)
A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis
B Goodwin et al.
MOLECULAR CELL (2000)
Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors
TT Lu et al.
MOLECULAR CELL (2000)
分享论文
